Look, I’ve spent the last decade watching pharma and medtech teams struggle with the same fundamental challenge: they need robust, privacy-compliant real-world evidence to win payer negotiations, support HTA submissions, and drive commercial strategy—but navigating the complex landscape of healthcare databases and selecting the right data partnerships remains frustratingly difficult.
The stakes have never been higher. Market access teams face increasingly skeptical payers demanding local, longitudinal outcomes data. HEOR directors need to demonstrate cost-effectiveness with evidence that regulators actually trust. And commercial intelligence leaders? They’re expected to deliver competitive insights and accurate market sizing while navigating a maze of data quality considerations, privacy regulations, and capability trade-offs across dozens of potential providers.
Here’s what’s changed recently. The FDA’s December 2025 guidance on using real-world evidence to support regulatory decision-making for medical devices removes significant barriers to leveraging de-identified, aggregated databases. The EMA’s advancing framework for real-world evidence in regulatory decisions signals similar momentum globally. Translation? RWE isn’t just nice-to-have anymore—it’s becoming table stakes for market access, reimbursement strategy, and lifecycle management.
But—and this is critical—not all healthcare databases are created equal. The difference between winning and losing an HTA negotiation or a reimbursement submission often comes down to data provenance, completeness, and how well your evidence addresses the specific methodological concerns that HTA bodies and payers consistently raise. Understanding which combination of data capabilities aligns with your strategic priorities requires expertise in both pharmaceutical commercialization and the evolving real-world evidence ecosystem.
Why Traditional Approaches to Healthcare Data Keep Falling Short
In my experience working with pharmaceutical market access teams across Continental Europe, I’ve noticed the same pattern repeatedly. Companies invest significant resources in real-world evidence programs, only to discover—often too late—that their data sources have critical gaps or don’t align with their actual use cases.
The most common failure mode? Data quality and reliability issues that undermine everything downstream. We’re talking about inconsistent coding across providers, missing variables for key clinical endpoints, incomplete longitudinal tracking when patients switch insurance plans, and fragmented records that make it nearly impossible to construct accurate treatment pathways. When your HEOR team builds a cost-effectiveness model on claims data that’s missing 30% of outpatient procedures, you’re not doing real-world evidence—you’re doing expensive guesswork.
Then there’s the integration nightmare. Most pharma companies end up working with multiple data sources: claims data from one provider, electronic health records from another, maybe registries for specific therapeutic areas. Linking these sources requires substantial data engineering effort, and even then you’re dealing with patient matching algorithms that introduce their own biases and limitations. According to ISPOR-ISPE best practices for RWD studies, transparency about data linkage methodology is essential—but the technical details of how different providers approach this challenge vary dramatically.
Now here’s what really keeps market access directors up at night: regulatory and payer acceptance variability. The FDA and EMA have made significant progress in recent years (the FDA’s 2021 considerations for RWE laid important groundwork), but implementation remains inconsistent. What satisfies one HTA body might be questioned by another. European payers have their own expectations around local data relevance that differ substantially from UK NICE requirements or French HAS standards.
And let’s talk about the elephant in the room: bias and causal inference in observational data. Selection bias, confounding by indication, immortal time bias… these aren’t just academic concerns. They’re the reason payers push back on pharma-sponsored RWE studies. When you’re trying to demonstrate comparative effectiveness using claims data, you need robust propensity score matching, sensitivity analyses, and ideally validation against randomized trial results. Without methodological rigor, your expensive RWE program becomes just another piece of promotional material that HTA bodies politely ignore.
The challenge many pharmaceutical companies face isn’t finding data providers—it’s determining which combination of capabilities aligns with their strategic priorities and use cases.
The Strategic Value of Aggregated, Multi-Source Healthcare Databases
So what actually works when you need decision-grade real-world evidence? The answer lies in comprehensive, properly curated, multi-source healthcare databases that are specifically designed for regulatory and reimbursement applications.
The key differentiator is aggregation at scale with privacy compliance built in from the start. Instead of cobbling together multiple fragmented sources, you need access to health insurance claims databases covering substantial population segments—ideally with longitudinal tracking that follows patients across care settings and over time. For Continental Europe specifically, comprehensive solutions provide Statutory Health Insurance claims data representing major insured populations, with complete diagnostic coding (ICD-10 variants), procedure codes, prescription records (ATC classification), and healthcare utilization patterns.
This isn’t raw data dumped from insurance systems. Analysis-ready datasets mean the heavy lifting of data standardization, validation, and quality assurance has already happened. Variables are harmonized. Coding inconsistencies are reconciled. Patient trajectories are constructed with appropriate washout periods and index date logic. The best providers enable you to go from contract signature to first meaningful insight in 48 hours, not 6 months.
But here’s what elevates certain capabilities above the rest: linkage to complementary data sources while maintaining privacy compliance. When claims data (which captures what was billed) can be enriched with elements from hospital discharge data (DRG databases revealing treatment intensity and outcomes) or outpatient quality metrics, you get a much richer picture of real-world treatment patterns. The EMA’s 2025 reflection paper on RWD in non-interventional studies specifically highlights the value of multi-source integration for generating credible evidence.
Understanding the trade-offs between different data models and provider capabilities requires expertise that most companies lack internally. The gap between licensing claims data and extracting actionable intelligence is substantial—this is where expert guidance becomes critical.
Real-World Applications: How Leading Teams Use RWE Databases
Let me walk you through how sophisticated pharma and medtech teams actually leverage aggregated healthcare databases for strategic advantage.
Market Sizing and Epidemiology with Local Granularity
Traditional market sizing relies on published prevalence studies, physician surveys, and… optimism. The problem? Published epidemiology rarely reflects current diagnostic patterns, treatment uptake, or regional variation. When you’re planning a product launch or justifying pipeline investment decisions, you need current, local data.
Here’s a real scenario: A medtech company preparing to launch a novel cardiac monitoring device in Continental Europe needed to size the addressable market for patients with specific arrhythmia patterns who weren’t adequately managed on current therapy. Using population-level epidemiology data derived from aggregated claims—validated against national statistical benchmarks—they identified not just national prevalence but region-by-region variation in diagnosis rates, treatment patterns, and hospital vs. outpatient management. This granularity (down to regional level) revealed that certain Eastern European markets had 35% higher diagnosis rates than expected from published literature, fundamentally changing their launch strategy and sales territory planning.
The methodology matters enormously here. According to guidelines from ISPOR’s Real-World Evidence Transparency Initiative, protocol registration and transparent reporting of hypothesis-evaluating studies builds stakeholder trust. When your market sizing uses clearly documented inclusion/exclusion criteria, validated algorithms for case identification, and sensitivity analyses around diagnostic coding patterns, payers take your numbers seriously.
HEOR and Health Technology Assessment Submissions
For HEOR teams supporting reimbursement dossiers, the quality and provenance of your real-world data can make or break negotiations. Pan-European HTA assessments increasingly expect local effectiveness data, not just extrapolations from international trials. National HTA bodies have specific methodological requirements around comparator selection, patient population representativeness, and bias mitigation.
A practical example: An oncology brand team needed to demonstrate real-world progression-free survival and treatment duration patterns for their recently approved therapy vs. standard of care in European clinical practice. Using longitudinal patient datasets from statutory health insurance claims—properly anonymized and GDPR-compliant under Article 9 protections for special category health data—they reconstructed treatment sequences, identified line-of-therapy progression, and measured time-to-discontinuation with appropriate censoring for loss-to-follow-up.
The key success factors? First, transparency about data source and study design (following FDA’s Real-World Evidence Program principles even for EU submissions). Second, validation against published registries to demonstrate external validity. Third, pre-specified sensitivity analyses addressing potential confounders like disease severity, prior treatment history, and comorbidity burden. This approach resulted in supplementary evidence that meaningfully informed pricing negotiations—something that wouldn’t have happened with a generic, poorly-documented RWE analysis.
Competitive Intelligence and Treatment Pattern Analysis
Commercial analytics and business intelligence teams need current market dynamics—not what the market looked like when the last data release was published six months ago. Real-world evidence databases enable near-real-time competitive intelligence when structured appropriately.
Consider brand performance tracking post-launch. Instead of relying on pharmacy sell-in data (which doesn’t tell you about actual patient starts, discontinuations, or switching patterns), claims-based treatment pathway databases reveal: Which products are used in first-line vs. second-line settings? What percentage of patients initiated on your brand remain on therapy at 6 months? When patients discontinue, where do they switch? Are there regional differences in uptake driven by hospital formulary decisions or physician prescribing preferences?
For medtech companies, hospital databases and DRG data provide visibility into device utilization patterns, length of stay associated with different procedural approaches, and complication rates that influence hospital purchasing decisions. This isn’t hypothetical—it’s the data that informs value-based contracting negotiations and helps commercial teams position products based on actual health system economics rather than marketing claims.
Patient Journey Mapping and Treatment Pathway Optimization
Understanding how patients actually navigate the healthcare system—as opposed to how clinical guidelines suggest they should—reveals opportunities for medical affairs strategies, patient support programs, and even clinical development decisions.
Longitudinal patient datasets enable true journey mapping: time from initial symptoms to diagnosis (diagnostic delay), treatment sequencing including switches and discontinuations, healthcare resource utilization across settings (outpatient visits, hospitalizations, emergency department use), and long-term outcomes including complications and comorbidity development. When you can quantify that the average patient with a specific condition sees 3.2 different specialists over 14 months before receiving appropriate therapy, you’ve identified a concrete problem that patient navigation programs or diagnostic awareness initiatives can address.
For rare diseases especially, where published literature is sparse and trial enrollment is challenging, real-world data provides the only practical way to understand natural history, treatment patterns, and unmet needs at population scale.
Regulatory Evolution: What the Latest Guidance Means for Your RWE Strategy
The regulatory landscape around real-world evidence has matured substantially—and recent guidance documents provide clearer pathways for using aggregated healthcare databases in regulatory decision-making.
The FDA’s December 2025 update on RWE for medical devices is particularly significant. It explicitly removes previous barriers to using de-identified, aggregated databases, recognizing that individual patient-level consent isn’t required when data is properly anonymized and used for public health or research purposes under existing regulatory frameworks. This matters enormously for medtech companies planning post-market surveillance studies or seeking to support new intended use claims with real-world effectiveness data.
For pharma, the FDA’s broader RWE Program continues to advance. While primary effectiveness claims for new drug approvals remain challenging territories for RWE (randomized trials are still the gold standard), supplemental indications, pediatric extrapolation, and post-approval safety studies increasingly leverage real-world data. The key is fitness-for-purpose: matching your data source, study design, and analytical approach to the specific regulatory question.
In Europe, the EMA’s evolving framework emphasizes transparency and reproducibility. The 2025 reflection paper on RWD in non-interventional studies provides practical guidance on data quality assessment, appropriate study designs for different questions (cohort studies, case-control designs, self-controlled designs), and how to address confounding in observational research. Notably, the paper acknowledges that well-conducted RWE studies using validated databases can provide complementary evidence to support regulatory decisions across the product lifecycle.
Navigating the Data Landscape: What to Look For
Let me be direct about something that often gets glossed over: not all claims databases or healthcare data repositories are suitable for regulatory-grade evidence generation. The difference between a marketing-oriented data product and one that can withstand HTA scrutiny comes down to documentation, validation, and transparency.
Privacy Compliance: More Than Just De-identification
GDPR compliance for health data (Article 9 special category data) requires more than just removing names and addresses. True anonymization under GDPR means the data cannot be re-identified using available means—including linkage to external datasets or use of quasi-identifiers.
This is why aggregated, privacy-by-design databases are fundamentally different from datasets that were pseudonymized after the fact. When data is collected and structured specifically for research and analytics purposes—with appropriate legal basis under applicable data protection regulations—you’re working within an established legal framework rather than trying to retrofit clinical data for secondary uses.
The recent regulatory updates I mentioned earlier? They specifically recognize properly anonymized, aggregated databases as lower-risk approaches that don’t require individual patient consent for research purposes. That’s a major enabler for large-scale RWE studies that would be logistically impossible under opt-in consent models.
Coverage and Population Representativeness
The claims data market includes providers with varying strengths across several key dimensions. Coverage breadth varies dramatically—some maintain longitudinal records covering hundreds of millions of patient lives across multiple regions and payer types, while others focus on specific geographies or populations with greater depth.
Geographic granularity matters for European operations. Some data sources provide national-level aggregates, while others enable regional stratification critical for launch planning and territory optimization. Therapeutic area depth also varies; certain providers excel in specific disease areas due to specialized data partnerships or enrichment strategies.
Population representativeness requires careful evaluation. Does the covered population reflect your target market demographics? Are commercially insured and publicly insured patients both represented? What about underserved populations that might be systematically excluded from certain databases?
Data Standardization and Interoperability
Here’s a practical challenge that every data science team faces: when you receive healthcare data, are the coding systems consistent and well-documented? Are diagnosis codes using standardized ICD-10 variants? Are medication records using ATC classification, national drug codes, or proprietary formulary systems? Are procedure codes harmonized across different national healthcare systems?
The Observational Health Data Sciences and Informatics (OHDSI) community has done important work on the OMOP Common Data Model for enabling consistent analyses across disparate databases. For pan-European work, you need databases that maintain regional coding standards while still being interoperable with international research frameworks.
Beyond coding standards, data completeness matters enormously. Claims data is excellent for capturing what was reimbursed but has inherent limitations: missing clinical variables like lab values, limited outcome data beyond healthcare utilization, and capture only within the insurance coverage period. Understanding these limitations—and transparently documenting them in your study protocol and results—is what separates credible RWE from wishful thinking dressed up as evidence.
Analytical Sophistication and Tools
Capabilities range from traditional query-based systems to AI-powered platforms offering real-time pattern recognition and predictive analytics. The choice depends on whether you need descriptive intelligence (what happened) or forward-looking insights (what’s likely to happen).
Some providers offer self-service analytics platforms where your team directly queries the data. Others provide full-service research support where their epidemiologists conduct analyses on your behalf. Still others combine both models—self-service for exploratory work, full-service for regulatory submissions requiring validated methodologies.
Consider also whether you need API access for integrating claims data into your existing analytical infrastructure, or whether standalone platforms with visualization tools meet your needs. The technical integration requirements vary substantially based on your organization’s data maturity and existing technology stack.
Validation and Quality Assurance
How do you know your database accurately represents the population you’re studying? External validation. For epidemiology studies in Continental Europe, that means comparing prevalence estimates to published data from national health institutes, validating demographic distributions against official statistics, and checking treatment patterns against published guidelines and registry data.
Leading providers routinely validate against national statistical benchmarks and publish those validation metrics. Not because they’re proud of hitting high accuracy rates, but because HTA bodies and payers will ask for exactly this type of validation—and if you can’t provide it, your RWE study loses credibility before they even review your methodology.
Ask potential data partners about their validation processes, audit trails, and quality assurance procedures. Request validation reports showing accuracy against external benchmarks. Look for transparency about limitations—providers who claim perfect data are either naive or dishonest.
Understanding Cost Models and Licensing Structures
The financial models vary as much as the technical capabilities. Some providers charge per-query or per-patient-record accessed. Others offer annual subscriptions with unlimited queries within defined parameters. Still others use project-based pricing where costs scale with analytical complexity and deliverable scope.
Consider also data refresh frequency and historical depth. Real-time data feeds command premium pricing but enable competitive intelligence that adjudicated claims (available months later) cannot support. Historical depth matters for longitudinal analyses—10+ years of patient history enables robust outcomes research that 2-3 years cannot.
The total cost of ownership extends beyond licensing fees. Factor in data engineering costs (if you’re receiving raw extracts), analytical resource requirements, compliance overhead, and opportunity costs of delayed insights.
Advanced Analytics and Emerging Capabilities
Now let’s talk about where healthcare databases are heading—and what capabilities forward-thinking teams are starting to leverage.
Machine Learning on Real-World Data: Opportunities and Pitfalls
ML-ready datasets—properly structured, cleaned, and feature-engineered for predictive modeling—enable sophisticated analyses that weren’t feasible five years ago. Predictive models for treatment response, disease progression, and healthcare resource utilization can inform everything from clinical trial design to value-based contracting strategies.
But here’s the critical caveat: garbage in, garbage out applies 10x with machine learning. If your training data has systematic missingness, selection bias, or measurement errors, your fancy neural network just learns to perpetuate those biases at scale. This is why starting with high-quality, validated datasets is non-negotiable for any serious ML application in healthcare.
The opportunity is substantial though. Advanced techniques like transportability analyses (extending trial results to real-world populations), propensity score weighting with machine learning-based confounder selection, and natural language processing on clinical notes (where available) can generate insights that traditional statistical approaches miss.
Synthetic Healthcare Data: Privacy-Preserving Innovation
One of the most promising developments in RWE is synthetic data generation. Using techniques like Generative Adversarial Networks (GANs) with differential privacy guarantees, specialized providers can create artificial patient cohorts that preserve the statistical properties of real-world claims data without containing any actual patient information.
Why does this matter? Several reasons. First, it enables scenario modeling and “what-if” analyses that aren’t constrained by historical data limitations. Want to project market outcomes if treatment guidelines change? Synthetic data lets you model that counterfactual. Second, it dramatically simplifies data sharing for collaborative research—no personal data means substantially reduced GDPR compliance burden. Third, it allows early access to representative population data for product planning before you’ve formally licensed real-world datasets.
The technical requirements are sophisticated (you need to validate that synthetic data maintains clinical fidelity and doesn’t memorize real patients), but when done properly, synthetic healthcare data is becoming a valuable complement to real-world claims and EHR databases.
Building Your RWE Capability: Strategic Recommendations
So if you’re a HEOR director, head of market access, or commercial intelligence leader looking to build or enhance your RWE capability, what should you actually do?
Start with Clear Use Case Definition
Don’t license expensive healthcare databases just because competitors are doing it. Define specific business questions first: Are you preparing for HTA negotiations requiring local effectiveness data? Do you need competitive intelligence for launch planning? Are you supporting label expansion with real-world safety evidence?
Different questions require different data. Market sizing needs broad population coverage and current diagnosis patterns. Treatment pathway analyses require longitudinal tracking with adequate follow-up. Safety studies need complete capture of adverse events and outcomes. Match your data source to your question, not the other way around.
Before evaluating specific data providers, define your requirements clearly. Expert consultants can help structure this requirements definition process to ensure you’re comparing options on the dimensions that actually matter for your use cases.
Invest in Methodology, Not Just Data
Access to claims databases doesn’t automatically produce credible evidence. You need epidemiologists who understand observational study design, statisticians who can properly address confounding and selection bias, and analysts who know how to construct patient cohorts with appropriate inclusion/exclusion criteria and index date logic.
If you’re building an internal capability, this means hiring or training these skills. If you’re working with external partners, it means evaluating not just their data access but their methodological expertise and track record of regulatory/payer acceptance.
Leverage Expert Guidance for Data Partnership Selection
The claims data landscape is complex, with dozens of providers offering overlapping but distinct capabilities. Coverage breadth, analytical tools, geographic focus, therapeutic depth, cost models, and domain expertise all vary substantially.
Understanding which combination of capabilities matches your specific needs requires deep market knowledge that most companies lack internally. Expert advisors who understand both your business objectives and the evolving data landscape can accelerate your path to value while avoiding costly mismatches between your requirements and provider strengths.
The gap between understanding what claims data can do and identifying which specific partnerships deliver optimal value is substantial. Navigating this landscape requires expertise in both pharmaceutical commercialization and the real-world evidence ecosystem. Most pharmaceutical companies benefit from guidance in this selection process rather than attempting to evaluate dozens of potential providers independently.
Embrace Transparency and Pre-Specification
The ISPOR RWE Transparency Initiative advocates for protocol registration before study execution and transparent reporting of all analytical choices. This isn’t bureaucratic overhead—it’s what separates exploratory data analysis (which has its place) from hypothesis-testing evidence that regulators and payers will accept.
Pre-specify your analytical plan. Document your patient identification algorithms. Report sensitivity analyses even when they weaken your story. This level of transparency builds credibility that no amount of fancy modeling can substitute for.
Think Beyond Single Studies: Build a Continuous Intelligence Capability
The most sophisticated teams don’t treat RWE as one-off projects. They build continuous market intelligence capabilities using refreshed real-world data to track emerging trends, monitor competitive dynamics, identify early signals of guideline changes affecting prescribing patterns, and inform portfolio strategy decisions with current evidence.
This requires infrastructure—data pipelines, analytical workflows, visualization dashboards—but the ROI is substantial when you can answer critical business questions in days rather than commissioning 6-month consulting projects.
The Pan-European Market: Why Local Data Matters
If you’re operating across Continental Europe specifically, you already know that market access is uniquely challenging—and uniquely data-dependent. Each national HTA framework creates substantial evidentiary requirements that generic international RWE often can’t satisfy.
National HTA bodies and payer organizations have clear preferences for local data when available. This isn’t just regulatory conservatism—it reflects real differences in clinical practice patterns, treatment guidelines, healthcare system structure, and patient populations between different European markets.
Consider what makes Continental Europe distinct: Statutory Health Insurance systems in many countries provide comprehensive data capture. Regional healthcare systems create variation in care delivery that affects treatment patterns. Strong primary and ambulatory care sectors mean different service mix than hospital-centric systems. National coding systems require local expertise to interpret correctly.
When you’re preparing HTA submissions or negotiating with national payer associations, having real-world evidence specifically from the relevant healthcare system—validated, representative, and analyzed according to local health economics standards—isn’t just helpful. It’s often the difference between optimal pricing and getting grouped into reference categories with established generics.
Looking Ahead: The Future of Healthcare Intelligence
Where is this heading? Several trends are converging to make real-world evidence and healthcare databases increasingly central to pharmaceutical strategy.
Regulatory momentum continues to build. The FDA’s advancing RWE program and the EMA’s pragmatic framework signal that well-conducted observational research using validated databases will play larger roles in regulatory decisions. The EU Health Data Space (EHDS) initiative aims to enable cross-border health data access for research, which could dramatically expand available evidence for multinational HTA submissions.
HTA bodies are explicitly asking for RWE. National reimbursement processes increasingly expect real-world effectiveness data. Multiple European HTA agencies are developing RWE evaluation frameworks. Several national health authorities are piloting conditional approvals requiring post-launch evidence generation. The market access landscape is moving toward continuous evidence generation rather than one-time regulatory approval followed by static claims.
AI and advanced analytics are maturing from experimental to operational. Predictive models for patient outcomes, treatment optimization algorithms, and automated evidence synthesis tools are moving from research publications to practical applications. But—and this is crucial—these advanced techniques only work when built on high-quality, well-documented data foundations.
Patient-centricity is driving demand for real-world outcomes beyond clinical efficacy. Payers want to know about quality of life, treatment burden, healthcare resource utilization, and patient preferences. Traditional trials don’t capture these endpoints well. Real-world data—especially when enriched with patient-reported outcomes—provides the evidence base for value-based pricing and contracting.
Common Questions from HEOR and Market Access Teams
How do I evaluate data quality when comparing healthcare database options?
Ask for validation reports showing accuracy against external benchmarks. Request detailed documentation of data provenance—where exactly does the data come from? What’s the capture completeness for key variables? What validation processes are applied before datasets are released? Look for transparency about limitations—providers who claim perfect data are either naive or dishonest. Expert advisors who have evaluated multiple providers can help you identify which validation claims are substantive vs. marketing.
What’s the difference between claims data, EHR data, and registry data for RWE studies?
Claims data captures everything that was reimbursed—diagnoses, procedures, prescriptions, healthcare utilization. It’s comprehensive for coverage and highly reliable for what’s captured, but limited on clinical details and outcomes. EHR data has richer clinical variables (lab values, vital signs, clinical notes) but more limited populations and capture is inconsistent across providers. Registries are disease-specific, clinically detailed, but smaller samples and often selection-biased toward specialized centers. Ideally, you’d integrate multiple sources—but that creates methodological complexity that requires expertise to navigate properly.
How do I address payer skepticism about industry-sponsored RWE?
Transparency and methodological rigor. Pre-register your protocols. Use established, validated databases rather than custom data collections. Follow published best practices (ISPOR guidelines). Include independent statistical reviewers. Report all analyses, including those that don’t support your product. And honestly—sometimes the answer is to commission independent academic research using your data rather than conducting industry-sponsored studies, especially for highly contentious claims.
What sample size do I need for a real-world effectiveness study?
It depends entirely on your research question, expected effect size, and analytical approach. Rare outcome studies need larger populations than common outcome studies. Propensity score matching typically requires larger samples than regression adjustment. As a rough guideline for Continental Europe: you need at least several hundred patients per treatment arm for comparative effectiveness, several thousand for reliable safety signal detection, and tens of thousands for robust epidemiology estimates with regional stratification.
Can synthetic data replace real-world data for regulatory submissions?
Not yet for primary evidence, but it’s evolving. Current regulatory guidance accepts synthetic data for exploratory analyses, scenario modeling, and supplemental evidence—but regulators still want to see validation against real-world outcomes. The trajectory suggests synthetic data will become more accepted as methodology matures and validation standards are established. For now, think of synthetic data as a complement to, not substitute for, real-world claims and EHR data.
Your Next Steps: Strategic Approach to Real-World Intelligence
The pharmaceutical and medtech landscape has fundamentally changed. Real-world evidence isn’t optional anymore—it’s essential for market access, reimbursement negotiations, and commercial success. But generating credible, defensible RWE requires more than just access to data. It requires:
Comprehensive healthcare databases with proven quality and validation. Privacy-compliant data infrastructure that satisfies GDPR and local regulations. Methodological expertise in observational study design and causal inference. Transparency in analytical approaches and honest reporting of limitations. And ultimately, strategic guidance in matching your specific requirements to the right combination of data capabilities.
Understanding what types of claims data exist and what questions they can answer is the first step. The second step—matching your requirements to the right combination of data sources, analytical capabilities, and domain expertise—requires guidance from professionals who understand both the pharmaceutical industry and the evolving real-world evidence ecosystem.
At MEDDDICAL, we specialize in helping pharmaceutical and medtech companies navigate this complex landscape. Our expertise spans both sides of the equation: deep understanding of pharmaceutical market access, HEOR, and commercial intelligence needs, combined with comprehensive knowledge of the data provider ecosystem across Continental Europe.
We don’t just point you toward databases—we help you define requirements, evaluate trade-offs, and identify the right partnerships that align with your strategic objectives. Whether you’re preparing HTA submissions, sizing market opportunities, building competitive intelligence capabilities, or conducting population-level epidemiology research, we’ve guided hundreds of teams in structuring their real-world evidence strategies for success.
Ready to explore strategic approaches to real-world intelligence that align with your business objectives?
Contact us to discuss your specific data requirements and discover how expert guidance can accelerate your path to market access success while avoiding costly mismatches.
For more insights on RWE strategy and practical applications, explore our related resources:
- Use Case: Pharma Market Sizing with Real-World Insurance Claims Data
- RWE Healthcare Datasets for Pharma
Sources & References
- U.S. Food and Drug Administration. (2025). Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices (Final Guidance). https://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-real-world-evidence-support-regulatory-decision-making-medical-devices
- U.S. Food and Drug Administration. (2021). Considerations for the Use of Real-World Data and Real-World Evidence to Support Regulatory Decision-Making for Drug and Biological Products. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-real-world-data-and-real-world-evidence-support-regulatory-decision-making-drug
- U.S. Food and Drug Administration. Real-World Evidence Program. https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence
- European Medicines Agency. Real-World Evidence Scientific Guidelines. https://www.ema.europa.eu/en/human-regulatory-overview/research-development/scientific-guidelines/clinical-efficacy-safety-guidelines/real-world-evidence
- European Medicines Agency. (2025). Reflection Paper on the Use of Real-World Data in Non-Interventional Studies to Generate Real-World Evidence. https://www.ema.europa.eu/en/reflection-paper-use-real-world-data-non-interventional-studies-generate-real-world-evidence-scientific-guideline
- ISPOR-ISPE Special Task Force. Good Practices for Real-World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR-ISPE Special Task Force on Real-World Evidence in Health Care Decision Making. https://www.ispor.org/heor-resources/good-practices/article/good-practices-for-real-world-data-studies-of-treatment-and-or-comparative-effectiveness
- ISPOR. Real-World Evidence Transparency Initiative. https://www.ispor.org/strategic-initiatives/real-world-evidence/real-world-evidence-transparency-initiative
- Observational Health Data Sciences and Informatics (OHDSI). OHDSI: Advancing Healthcare Through Open Science. https://www.ohdsi.org/
- European Commission. European Health Data Space (EHDS): Proposal for a Regulation. https://eur-lex.europa.eu/
- National Health Institutes and Statistical Offices. Population Health Statistics and Epidemiological Benchmarks (Various national sources across Continental Europe).